Robin Nilson

Title: Robin Nilson: Innovator in Adenovirus Research

Introduction

Robin Nilson is a prominent inventor based in Ulm, Germany. He has made significant contributions to the field of virology, particularly in the development of adenovirus-based therapies. His innovative work focuses on modifying adenovirus proteins to enhance their therapeutic potential.

Latest Patents

Robin Nilson holds a patent for an invention titled "Adenovirus comprising a modified adenovirus hexon protein." This invention discloses a human adenovirus species C that features a capsid containing a modified adenovirus hexon protein. The modified hexon protein includes a modified HVR1 region with the sequence DEAATALEINLKKKKQAEQQ (SEQ ID NO.: 1). The patent outlines the use of this adenovirus in treating or preventing human diseases. Additionally, it describes a nucleic acid encoding the modified adenovirus hexon protein and its application in transducing mesenchymal stromal cells (MSCs) or tumor cells. The invention also includes an in vitro method for transducing MSCs and a transduced MSC that can be utilized in disease treatment.

Career Highlights

Robin Nilson is affiliated with Universitat Ulm, where he conducts his research and development activities. His work has garnered attention for its potential applications in medical therapies, particularly in the context of gene therapy and cancer treatment.

Collaborations

He collaborates with notable colleagues, including Stefan Kochanek and Lea Krutzke, who contribute to the advancement of his research initiatives.

Conclusion

Robin Nilson's innovative work in adenovirus research exemplifies the potential of modified viral vectors in therapeutic applications. His contributions are paving the way for new treatment options in the medical field.